US equities |
MU $1,097.39 ▲+3.03% NVDA $230.86 ▲+1.09% SNDK $1,787.69 ▲+2.75% INTC $120.00 ▼-0.19% AAPL $330.32 ▼-0.81% GOOGL $338.24 ▼-1.70% TSLA $354.11 ▼-0.20% AMD $615.73 ▲+0.65%
FinancialContent

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

4.550 -0.170 (-3.60%)
Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,463
Open 4.547
Bid (Size) 4.500 (200)
Ask (Size) 4.720 (100)
Prev. Close 4.720
Today's Range 4.547 - 4.550
52wk Range 2.980 - 63.90
Shares Outstanding 145,148,593
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
This strategic engagement is designed to strengthen NeuroThera’s U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public‑health importance of advancing... 
Via TheNewswire.com

Performance

YTD
-63.9%
-63.9%
1 Month
-31.4%
-31.4%
3 Month
-11.7%
-11.7%
6 Month
+24.3%
+24.3%
1 Year
-91.6%
-91.6%

More News

Read More
News headline image
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
From SciSparc Ltd
Via GlobeNewswire
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
From SciSparc Ltd
Via GlobeNewswire
News headline image
NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
Via TheNewswire.com
News headline image
Neurothera Labs Inc. Announces Share Consolidation
Via TheNewswire.com
News headline image
NeuroThera Labs Engages Dr. Reuter Investor Relations
Via TheNewswire.com
News headline image
SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics
From SciSparc Ltd
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-07-29: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
These stocks are moving in today's session ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
Which stocks are gapping on Thursday? ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill

Frequently Asked Questions

Is SciSparc Ltd. - Ordinary Shares publicly traded?
Yes, SciSparc Ltd. - Ordinary Shares is publicly traded.
What exchange does SciSparc Ltd. - Ordinary Shares trade on?
SciSparc Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for SciSparc Ltd. - Ordinary Shares?
The ticker symbol for SciSparc Ltd. - Ordinary Shares is SPRC on the Nasdaq Stock Market
What is the current price of SciSparc Ltd. - Ordinary Shares?
The current price of SciSparc Ltd. - Ordinary Shares is 4.550
When was SciSparc Ltd. - Ordinary Shares last traded?
The last trade of SciSparc Ltd. - Ordinary Shares was at 10/01/26 04:00 PM ET
What is the market capitalization of SciSparc Ltd. - Ordinary Shares?
The market capitalization of SciSparc Ltd. - Ordinary Shares is 660.43M
How many shares of SciSparc Ltd. - Ordinary Shares are outstanding?
SciSparc Ltd. - Ordinary Shares has 660M shares outstanding.